Table 3. Comparison of clinicopathological characteristics between PD-L1 positive and negative groups in ADC patients.
| Characteristics | PD-L1 | P value | |
|---|---|---|---|
| <1% (n=81) | ≥1% (n=55) | ||
| Age (years) | 64.73±9.39 | 66.47±8.37 | 0.269 |
| Sex | 0.019 | ||
| Female | 35 (43.2) | 13 (23.6) | |
| Male | 46 (56.8) | 42 (76.4) | |
| BMI (kg/m2) | 23.06±3.54 | 22.13±3.38 | 0.128 |
| WBC (×109/L) | 6.40 (5.40–7.95) | 8.40 (6.80–10.30) | <0.001 |
| Neutrophils (×109/L) | 4.60 (3.55–6.25) | 5.10 (3.80–6.90) | 0.199 |
| Lymphocytes (×109/L) | 1.56±0.56 | 1.57±0.65 | 0.907 |
| NLR | 2.86 (2.10–4.39) | 3.31 (2.47–6.21) | 0.058 |
| BUN/Cr | 85.41±22.43 | 92.80±24.41 | 0.071 |
| Alb (g/L) | 38.78±4.05 | 37.50±5.84 | 0.163 |
| LDH (U/L) | 217.10 (178.70–407.25) | 230.60 (174.10–312.10) | 0.338 |
| T12 SMD (HU) | 47.49±11.09 | 48.04±12.24 | 0.783 |
| SMI | 1,098.50±280.22 | 1,090.27±293.61 | 0.869 |
| Clinical stage | 0.002 | ||
| III | 9 (11.1) | 18 (32.7) | |
| IV | 72 (88.9) | 37 (67.3) | |
| CEA (ng/mL) | 15.28 (4.85–81.42) | 4.28 (2.12–9.70) | <0.001 |
| NSE (ng/mL) | 22.18 (15.72–57.45) | 17.30 (10.49–23.79) | 0.001 |
| CY21-1 (ng/mL) | 6.21 (3.26–14.96) | 6.20 (2.57–14.92) | 0.698 |
| Stage | |||
| T | 0.002 | ||
| 1 | 11 (13.6) | 15 (27.3) | |
| 2 | 16 (19.8) | 18 (32.7) | |
| 3 | 15 (18.5) | 8 (14.5) | |
| 4 | 39 (48.1) | 14 (25.5) | |
| N | 0.056 | ||
| 0 | 11 (13.6) | 11 (20.0) | |
| 1 | 2 (2.5) | 5 (9.1) | |
| 2 | 30 (37.0) | 21 (38.2) | |
| 3 | 38 (46.9) | 18 (32.7) | |
| M | 0.002 | ||
| 0 | 9 (11.1) | 18 (32.7) | |
| 1 | 72 (88.9) | 37 (67.3) | |
Data are presented as mean ± SD, median (25–75th percentiles), or n (%). PD-L1, programmed cell death-ligand 1; ADC, adenocarcinoma; BMI, body mass index; WBC, white blood cell; NLR, neutrophil to lymphocyte ratio; BUN, blood urea nitrogen; Cr, creatinine; Alb, albumin; LDH, lactic dehydrogenase; T12 SMD, skeletal muscle density at the level of the T12; SMI, skeletal muscle index; CEA, carcinoembryonic antigen; NSE, neuron specific enolase; CY21-1, cytokeratin 19 fragment; T, tumor; N, node; M, metastasis; SD, standard deviation.